From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

New Approach to Peanut Allergy

A monoclonal antibody against IgE might prevent severe allergic reactions in peanut-sensitive patients.

Antigen-specific IgE presumably mediates allergic reactions to peanuts. In this industry-supported, randomized, double-blind trial, researchers sought to determine the effect of a monoclonal antibody directed against IgE in 82 patients (mean age, 32) with histories of immediate hypersensitivity to peanuts. The anti-IgE antibody prevents binding of IgE to mast cells and basophils.

For each patient, the researchers first determined the threshold amount of ingested peanut flour that would trigger an allergic response; the mean threshold was 331 mg. Then, the patients were assigned to receive 4 monthly subcutaneous injections of placebo or 1 of 3 doses of anti-IgE. Several weeks after the final injection, each patient underwent another peanut challenge: The mean amount of ingested peanut flour required to elicit symptoms increased by 710 mg in placebo recipients and by 913 mg, 1650 mg, and 2627 mg, respectively, in the groups that received the 3 escalating doses of anti-IgE. This trend -- an increasing threshold of sensitivity with increasing doses of anti-IgE -- was statistically significant. No serious side effects were reported.

Comment: Despite the best efforts of peanut-allergic patients, they still inadvertently ingest foods containing peanut products and occasionally experience life-threatening reactions. The approach outlined in this study holds promise for ameliorating this concern, but the authors note that additional trials are necessary before anti-IgE is approved for general use.

— Allan S. Brett, MD

Published in Journal Watch General Medicine April 1, 2003

Citation(s):

Leung DYM et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003 Mar 13; 348:986-93.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2003. Massachusetts Medical Society. All rights reserved.